Completed NA INTERVENTIONAL 2-arm NCT06676293

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

Compassionate Use of Combination Therapy with Asparaginase and Pembrolizumab in Patients with Nasopharyngeal Carcinoma

Sponsor: Chang Gung Memorial Hospital

Conditions Nasopharyngeal Carcinoma (NPC)

Updated 2 times since 2024 Last updated: Nov 6, 2024 Started: Aug 1, 2023 Primary completion: Apr 30, 2024 Completion: Aug 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Nasopharyngeal Carcinoma (NPC) and is currently completed. Chang Gung Memorial Hospital leads this study, which shows 2 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Dec 2024 — Sep 2025 [monthly]

Completed NA

First recorded

Aug 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chang Gung Memorial Hospital

Data source: Chang Gung Memorial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taoyuan, Taiwan